晚期卵巢癌新辅助化疗患者肌少症发生率更高:预康复的机会
本研究比较了晚期上皮性卵巢癌患者接受初次肿瘤细胞减灭术(PCS)与新辅助化疗/间歇性肿瘤细胞减灭术(NACT/ICS)时的基线体成分指标,发现NACT患者肌少症比例显著更高(40.0% vs 27.5%,p=0.04),且NACT期间骨骼肌指数显著下降(-1.4 cm2/m2,p=0.005)。
要点
- NACT患者肌少症发生率显著高于PCS患者(40.0% vs 27.5%,p=0.04)。
- NACT患者平均骨骼肌面积(107.3 vs 113.4 cm2,p=0.004)更低。
- NACT期间骨骼肌指数平均下降1.4 cm2/m2(p=0.005)。
核心结论
- 在循证分诊系统下,接受NACT的晚期EOC患者肌少症比接受PCS者更常见。
- NACT过程中体成分发生显著变化,肌少症可能是虚弱指标并需纳入治疗计划考虑。
研究设计与样本
- 回顾性队列研究,纳入2012年1月1日至2016年7月31日期间接受PCS或NACT/ICS的IIIC/IV期EOC患者。
- 共纳入200例PCS患者和85例NACT/ICS患者,其中76例有NACT前和ICS前两次扫描。
- 通过半自动化程序评估CT扫描确定体成分指标(SMA、SMD、SMI、SMG),肌少症定义为SMI<39.0 cm2/m2。
主要发现
- NACT患者肌少症比例显著高于PCS患者(40.0% vs 27.5%,p=0.04)。
- NACT患者平均SMA较低(107.3 vs 113.4 cm2,p=0.004),平均SMG有降低趋势(1344.6 vs 1456.9 (cm2 x HU)/m2,p=0.06)。
- NACT/ICS患者手术时平均SMI显著下降-1.4 cm2/m2(p=0.005),肌少症比例从基线40.8%升至50.0%(p=0.09,无统计学显著性)。
关键数值与推荐
- 肌少症定义:SMI<39.0 cm2/m2。
- 体成分指标包括SMA、SMD、SMI和SMG,通过CT半自动化程序评估。
临床怎么用
- 对计划接受NACT的晚期EOC患者应评估肌少症,考虑预康复干预。
- 肌少症可作为虚弱指标,在治疗分诊和计划中予以考虑。
局限性
- 样本量有限(NACT/ICS组85例,其中仅76例有两次扫描)。
- 回顾性研究设计。
- 肌少症比例变化无统计学显著性(p=0.09)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare baseline body composition measures (BCM), including sarcopenia, between patients with advanced epithelial ovarian cancer (EOC) undergoing primary cytoreductive surgery (PCS) versus neoadjuvant chemotherapy/interval cytoreductive surgery (NACT/ICS) and evaluate changes in BCM pre-NACT versus pre-ICS. METHODS: Patients with stage IIIC/IV EOC who underwent PCS or NACT with curative intent between 1/1/2012 and 7/31/2016 were included. Computed tomography scans were evaluated via a semi-automated program to determine BCM. Measures evaluated include skeletal muscle area (SMA), skeletal muscle density (SMD), skeletal muscle index (SMI), and skeletal muscle gauge (SMG). Sarcopenia was defined as SMI <39.0 cm2/m2. RESULTS: The study included 200 PCS patients and 85 NACT/ICS patients, of which 76 had both pre-NACT and pre-ICS scans. NACT patients were significantly more likely to be sarcopenic compared to PCS patients (40.0% vs 27.5%, p = 0.04). Mean SMA (107.3 vs 113.4 cm2, p = 0.004) and mean SMG (1344.6 vs. 1456.9 (cm2 x HU)/m2, p = 0.06) were lower in NACT patients. Among NACT/ICS patients, mean SMI significantly decreased -1.4 cm2/m2 (p = 0.005) at the time of surgery, resulting in a non-statistically significant increase in the percentage of sarcopenic patients from baseline (40.8% vs. 50.0%, p = 0.09). CONCLUSIONS: Sarcopenia is more common in patients with advanced EOC undergoing NACT compared to PCS when using an evidence-based triage system for triage decisions. Body composition changes significantly over the course of NACT. Sarcopenia may be an indicator of debility and another factor for consideration in treatment planning. Further research into body composition's effects on prognosis and altering sarcopenia is necessary.
引用
- Fadadu PP, Polen-De CL, McGree ME, et al. Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation. Gynecol Oncol. 2020. PMID: 33109391. doi:10.1016/j.ygyno.2020.10.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。